Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Leukemia Research

Volumn 38, Issue 2, 2014, Pages 198-203

  Mauro, Francesca R ^a   Molica, Stefano ^b   Laurenti, Luca ^c   Cortelezzi, Agostino ^d   Carella, Angelo M ^e   Zaja, Francesco ^f   Chiarenza, Annalisa ^g   Angrilli, Francesco ^h   Nobile, Francesco ⁱ   Marasca, Roberto ^j   Musolino, Caterina ^k   Brugiatelli, Maura ^l   Piciocchi, Alfonso ^m   Vignetti, Marco ^m   Fazi, Paola ^m   Gentile, Giuseppe ^a   De Propris, Maria S ^a   Starza, Irene Della ^a   Marinelli, Marilisa ^a   Chiaretti, Sabina ^a   Del Giudice, Ilaria ^a   Nanni, Mauro ^a   Albano, Francesco ⁿ   Cuneo, Antonio ^o   Guarini, Anna ^a   Foà, Robin ^a   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b PUGLIESE CIACCIO HOSPITAL   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF UDINE   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h Local Health Unit of Pescara   (Italy)

ⁱ BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^j UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^k UNIVERSITY OF MESSINA   (Italy)

^l Azienda Ospedaliera Papardo   (Italy)

^m Italian Group for Adult Hematologic Diseases GIMEMA Data Center   (Italy)

ⁿ UNIVERSITY OF BARI   (Italy)

^o UNIVERSITY HOSPITAL OF FERRARA   (Italy)

more..

Author keywords

Alemtuzumab; Biology; Chronic lymphocytic leukemia; CLL; Fludarabine; Young

Indexed keywords

ALEMTUZUMAB PLUS FLUDARABINE; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; COTRIMOXAZOLE; UNCLASSIFIED DRUG; VALACICLOVIR; ALEMTUZUMAB; FLUDARABINE; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DISEASE DURATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GRANULOCYTOPENIA; HUMAN; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RICHTER SYNDROME; SURVIVAL TIME; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIDARABINE;

EID: 84892510314     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.11.009     Document Type: Article

References (35)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J Clin 2010, 60(5):277-300.
2. Shanafelt T.D., Rabe K.G., Kay N.E., Zent C.S., Jelinek D.F., Reinalda M.S., et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer 2010, 116(20):4777-4787.
3. Mauro F.R., Foa R., Giannarelli D., Cordone I., Crescenzi S., Pescarmona E., et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999, 94(2):448-454.
4. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94(6):1840-1847.
5. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94(6):1848-1854.
6. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., et al. ZAP-70expression as a surrogate for immunoglobulin variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348(18):1764-1775.
7. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Kröber A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343(26):1910-1916.
8. Del Giudice I., Mauro F.R., De Propris M.S., Santangelo S., Marinelli M., Peragine N., et al. White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia. Haematologica 2011, 96(4):626-630.
9. Dohner H., Stilgenbauer S., James M.R., Benner A., Weilguni T., Bentz M., et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997, 89(7):2516-2522.
10. Dohner H., Fischer K., Bentz M., Hansen K., Benner A., Cabot G., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995, 85(6):1580-1619.
11. Cordone I., Masi S., Mauro F.R., Soddu S., Morsilli O., Valentini T., et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998, 91(11):4342-4349.
12. Zenz T., Krober A., Scherer K., Häbe S., Bühler A., Benner A., et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008, 112(8):3322-3329.
13. Keating M.J., O'Brien S., Albitar M., Lerner S., Plunkett W., Giles F., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23(18):4079-4088.
14. Hallek M., Fischer K., Fingerle-Rowson G., Fink A.M., Busch R., Mayer J., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747):1164-1174.
15. Keating M.J., Flinn I., Jain V., Binet J.L., Hillmen P., Byrd J., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99(10):3554-3561.
16. Karlsson C., Lundin J., Kimby E., Kennedy B., Moreton P., Hillmen P., et al. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 2009, 144(1):78-85.
17. Stilgenbauer S., Zenz T., Winkler D., Bühler A., Schlenk R.F., Groner S., et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009, 27(24):3994-4001.
18. Hillmen P., Skotnicki A.B., Robak T., Jaksic B., Dmoszynska A., Wu J., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25(35):5616-5623.
19. Elter T., Borchmann P., Schulz H., Reiser M., Trelle S., Schnell R., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005, 23(28):7024-7031.
20. Elter T., Gercheva-Kyuchukova L., Pylylpenko H., Robak T., Jaksic B., Rekhtman G., et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol 2011, 12(13):1204-1213.
21. Schweighofer C.D., Ritgen M., Eichhorst B.F., Busch R., Abenhardt W., Kneba M., et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission-long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009, 144(1):95-98.
22. Lin T.S., Donohue K.A., Byrd J.C., Lucas M.S., Hoke E.E., Bengtson E.M., et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 2010, 28(29):4500-4506.
23. Schetelig J., van Biezen A., Brand R., Lucas M.S., Hoke E.E., Bengtson E.M., et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17 p deletion. A retrospective European group for blood and marrow transplantation analysis. J Clin Oncol 2008, 26(31):5094-5100.
24. Dreger P., Döhner H., Ritgen M., Böttcher S., Busch R., Dietrich S., et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial. Blood 2010, 116(14):2438-2447.
25. Sutton L., Chevret S., Tournilhac O., Diviné M., Leblond V., Corront B., et al. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood 2011, 117(23):6109-6119.
26. Dreger P., Döhner H., McClanahan F., Busch R., Ritgen M., Greinix H., et al. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the GCLLSG CLL3 trial. Blood 2012, 10.1182/blood-2011-09-378505.
27. Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, 48(1):198-206.
28. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating M.J., O'Brien S., et al. National Cancer Institute-sponsored Working Group lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87(12):4990-4997.
29. Chiaretti S., Tavolaro S., Marinelli M., Messina M., Del Giudice I., Mauro F.R., et al. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling. Genes Chromosomes Cancer 2011, 50(4):263-274.
30. Guarini A., Marinelli M., Tavolaro S., et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 2012, 97(1):47-55.
31. Stilgenbauer S., Eichhorst B.F., Busch R., et al. Biologic and clinical markers for outcome after fludarabine (F) or F plus cyclophosphamide (FC): comprehensive analysis of the CLL4 trial of the GCLLSG. Blood 2008, 112(11):2089. Abstract 2089.
32. Schnaiter A., Paschka P., Rossi M., et al. NOTCH1, SF3B1 and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 2013, [Epub ahead of print].
33. Gaidano G., Foà R., Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest 2012, 122(10):3432-3438.
34. Ding W., Ferrajoli A. Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion. Hematol Am Soc Hematol Educ Program 2010, 2010:90-92.
35. Fischer K., Cramer P., Busch R., Böttcher S., Bahlo J., Schubert J., et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012, 30(26):3209-3216.